Network and Experimental Pharmacology on Mechanism of Yixintai Regulates the TMAO/PKC/NF-κB Signaling Pathway in Treating Heart Failure
Ziyan Wang,Chengxin Liu,Jiaming Wei,Hui Yuan,Min Shi,Fei Zhang,Qinghua Zeng,Aisi Huang,Lixin Du,Ya Li,Zhihua Guo
DOI: https://doi.org/10.2147/dddt.s448140
IF: 4.3188
2024-04-30
Drug Design Development and Therapy
Abstract:Ziyan Wang, 1, 2, &ast Chengxin Liu, 1, 2, &ast Jiaming Wei, 2, 3 Hui Yuan, 1, 2 Min Shi, 2, 3 Fei Zhang, 2, 3 Qinghua Zeng, 2, 3 Aisi Huang, 2, 3 Lixin Du, 4 Ya Li, 4 Zhihua Guo 2, 3 1 First Clinical College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China; 2 Hunan Key Laboratory of Colleges and Universities of Intelligent Traditional Chinese Medicine Diagnosis and Preventive Treatment of Chronic Diseases of Hunan Universities of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China; 3 School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China; 4 School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ya Li; Zhihua Guo, Email ; Objective: This study aims to explore the mechanism of action of Yixintai in treating chronic ischemic heart failure by combining bioinformatics and experimental validation. Materials and Methods: Five potential drugs for treating heart failure were obtained from Yixintai (YXT) through early mass spectrometry detection. The targets of YXT for treating heart failure were obtained by a search of online databases. Gene ontology (GO) functional enrichment analysis and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses were conducted on the common targets using the DAVID database. A rat heart failure model was established by ligating the anterior descending branch of the left coronary artery. A small animal color Doppler ultrasound imaging system detected cardiac function indicators. Hematoxylin-eosin (HE), Masson's, and electron microscopy were used to observe the pathological morphology of the myocardium in rats with heart failure. The network pharmacology analysis results were validated by ELISA, qPCR, and Western blotting. Results: A total of 107 effective targets were obtained by combining compound targets and eliminating duplicate values. PPI analysis showed that inflammation-related proteins (TNF and IL1B) were key targets for treating heart failure, and KEGG enrichment suggested that NF-κB signaling pathway was a key pathway for YXT treatment of heart failure. Animal model validation results indicated the following: YXT can significantly reduce the content of intestinal microbiota metabolites such as trimethylamine oxide (TMAO) and improve heart failure by improving the EF and FS values of heart ultrasound in rats and reducing the levels of serum NT-proBNP, ANP, and BNP to improve heart failure. Together, YXT can inhibit cardiac muscle hypertrophy and fibrosis in rats and improve myocardial ultrastructure and serum IL-1β, IL-6, and TNF-α levels. These effects are achieved by inhibiting the expressions of NF-κB and PKC. Conclusion: YXT regulates the TMAO/PKC/NF-κB signaling pathway in heart failure. Keywords: heart failure, yixintai, TMAO, PKC/NF-κB pathway, traditional Chinese medicine, network pharmacology Heart failure (HF) is the primary cause of death in patients with cardiovascular disease. 1 HF is characterized by heart structural or functional failure, leading to impaired ventricular filling and ejection function, inability of the heart to provide sufficient blood to tissues to meet metabolic needs, pulmonary and systemic circulation congestion, and organ and tissue perfusion. Clinical manifestations include dyspnea, physical activity limitation, and fluid retention. Approximately 2% of adults globally have HF, with poor prognosis and high hospitalization and mortality rates. 2 Despite significant progress in treating heart failure, patient readmission and cardiac events remain high. Therefore, it is crucial to research and develop drugs for HF. 3,4 Many studies have demonstrated the impact of the gut microbiota on HF pathogenesis, and the substances secreted by the gut microbiota are closely related to HF occurrence and progression. Multiple studies have shown a close relationship between intestinal microbiota secretion, trimethylamine oxide (TMAO), and HF occurrence and development. 5,6 Protein kinase C (PKC) is crucial in most G-protein-mediated receptors mediating biological effects and often acts upstream of nuclear factor kappa-B (NF-κB) by participating in IkB phosphorylation, which binds to NF-κB, dissociates, and causes NF-κB activation. 7 After activatio -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal